DEFA14A: Premier to Go Private in $28.25/Share Patient Square Deal

Premier, Inc. announced its acquisition by Patient Square Capital for $28.25 per share in cash, taking the company private.

Summary

• Premier, Inc. will be acquired by an affiliate of Patient Square Capital, a dedicated healthcare investment firm.
• The transaction will take Premier private, resulting in its stock no longer being listed or traded on NASDAQ or any other public exchange.
• Stockholders will receive $28.25 in cash for each share upon the closing of the transaction.
• Premier's Board of Directors unanimously determined that this transaction is in the best interests of Premier and its stockholders, delivering immediate and certain value.
• The transaction is expected to be completed by the first quarter of calendar year 2026.
• Closing is subject to approval by Premier stockholders, satisfaction of regulatory approvals, and other customary closing conditions.
• Premier will continue to operate as a public company until the transaction closes, with no immediate impact on its operations or services.

Sentiment

Score: 8

Explanation: The acquisition offers immediate and certain value to stockholders at a fixed price, and the company anticipates significant benefits from private ownership, including enhanced financial flexibility and resources for innovation and growth. However, it also means the company will no longer be publicly traded.

Positives

• Provides immediate and certain value to stockholders at $28.25 per share.
• Patient Square Capital brings deep industry expertise, significant capital, and a strong track record in healthcare investments.
• Premier will benefit from enhanced financial flexibility and access to additional capital and resources as a private company.
• The acquisition is expected to accelerate the advancement and tech-enablement of Premier's product portfolio.
• It will enable Premier to capitalize on emerging opportunities and continue innovation to meet evolving member needs.
• Patient Square's interest validates Premier's industry leadership in supply chain expertise, world-class technology, and nationally recognized advisory capabilities.

Negatives

• Premier stock will no longer be listed or trade on NASDAQ or any other public exchange upon closing.
• Existing public stockholders will no longer participate in any potential future upside beyond the $28.25 per share acquisition price.

Risks

• Inability to consummate the proposed transaction within the anticipated time period, or at all, due to reasons such as failure to obtain required regulatory approvals.
• Failure to satisfy other conditions to the consummation of the proposed transaction, including obtaining necessary stockholder approval.
• Risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Premier Class A Common Stock.
• Disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel.
• Difficulty in maintaining relationships with customers, vendors, and other business partners.
• Occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement.
• Risks related to disruption of current plans and operations or the diversion of management's attention from ongoing business operations due to the proposed transaction.
• Significant transaction costs associated with the acquisition.
• Risk of litigation and/or regulatory actions related to the proposed transaction.
• Unfavorable results from currently pending litigation and proceedings or litigation and proceedings that could arise in the future.

Future Outlook

The transaction is expected to close by the first quarter of calendar year 2026, subject to stockholder and regulatory approvals. Premier anticipates enhanced financial flexibility and resources as a private company under Patient Square Capital's ownership, enabling accelerated product portfolio advancement, tech-enablement, and innovation.

Management Comments

• Premier's Board of Directors carefully considered a wide range of strategic alternatives in recent years and unanimously determined that this transaction with Patient Square is in the best interests of Premier and its stockholders and, upon closing, will deliver immediate and certain value to our stockholders.
• Patient Square has deep industry expertise, significant capital and a strong track record of successfully helping companies like Premier reach their full potential.
• As a private company with Patient Square's financial support, Premier will benefit from access to additional capital and resources.
• This means that, under Patient Square's ownership, Premier will have enhanced financial flexibility to accelerate the advancement and tech-enablement of our product portfolio, capitalize on emerging opportunities and continue pushing the envelope of innovation – all designed to meet your evolving needs.
• Patient Square's interest in Premier is a testament to the strength of our ongoing partnership.
• We expect to complete the transaction by the first quarter of calendar year 2026, subject to approval by Premier stockholders and satisfaction of regulatory approvals and other customary closing conditions.
• Until then, we will continue to operate as a public company, and it is business as usual. This announcement has no impact on the way Premier operates or serves you.

Industry Context

The acquisition of Premier by Patient Square Capital reflects a broader trend of private equity firms investing in the healthcare sector, particularly in companies offering supply chain solutions, technology, and advisory services. This move allows Premier to leverage specialized healthcare investment expertise and capital, potentially accelerating innovation and market penetration in a competitive and evolving healthcare landscape, similar to other healthcare tech and service providers seeking strategic partners for growth and operational efficiency.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Will receive $28.25 in cash per share, providing immediate and certain value, but will no longer hold shares in a publicly traded company.
• Members (Customers): Premier expects to invest further in capabilities, accelerate product advancement, and enhance innovation to meet evolving needs, aiming to elevate patient care and improve healthcare.
• Employees: The announcement states 'it is business as usual' until closing, but the risk section mentions 'retaining and hiring key personnel' as a potential challenge.
• Vendors/Business Partners: The risk section mentions 'maintaining relationships with the Company's customers, vendors and others with whom it does business' as a potential challenge.

Next Steps

• Premier will file relevant materials with the U.S. Securities and Exchange Commission (SEC), including a proxy statement on Schedule 14A.
• The proposed transaction will be submitted to Premier's stockholders for their consideration and approval.
• The transaction is subject to satisfaction of regulatory approvals and other customary closing conditions.
• Premier will continue to operate as a public company until the transaction closes.
• The transaction is expected to be completed by the first quarter of calendar year 2026.

Key Dates

Recommendation

Existing shareholders should hold their shares to receive the $28.25 per share cash payout upon the expected closing of the transaction. The Board has unanimously approved the deal, providing immediate and certain value. For investors seeking arbitrage opportunities, a 'buy' might be considered if the current market price is below the offer price, assuming high confidence in the deal's completion by Q1 2026.

Keywords

Premier Inc, Patient Square Capital, Acquisition, Take-private, Healthcare, Supply Chain, Merger, Stock Delisting, Private Equity, Shareholder Value